Comparative safety of concurrent adjuvant trastuzumab emtansine <i>versus</i> trastuzumab with radiotherapy in HER2-positive early breast cancer

Mine Aysan, Bahadir Koylu, Ayberk Bayramgil, Dilek Unal, Banu Karaalioğlu, Ahmet Bilici, Fatih Selçukbiricik, Ozcan Yildiz, Ömer Fatih Olmez

Open source

DOI: 10.1093/oncolo/oyag372
Published: 2026-09-21
Container: The Oncologist
Publisher: Oxford University Press (OUP)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/oncolo/oyag372,
  title = {Comparative safety of concurrent adjuvant trastuzumab emtansine
                    <i>versus</i>
                    trastuzumab with radiotherapy in HER2-positive early breast cancer},
  author = {Mine Aysan and Bahadir Koylu and Ayberk Bayramgil and Dilek Unal and Banu Karaalioğlu and Ahmet Bilici and Fatih Selçukbiricik and Ozcan Yildiz and Ömer Fatih Olmez},
  year = {2026},
  journal = {The Oncologist},
  doi = {10.1093/oncolo/oyag372},
  url = {https://doi.org/10.1093/oncolo/oyag372}
}

RIS

TY  - JOUR
TI  - Comparative safety of concurrent adjuvant trastuzumab emtansine
                    <i>versus</i>
                    trastuzumab with radiotherapy in HER2-positive early breast cancer
AU  - Mine Aysan
AU  - Bahadir Koylu
AU  - Ayberk Bayramgil
AU  - Dilek Unal
AU  - Banu Karaalioğlu
AU  - Ahmet Bilici
AU  - Fatih Selçukbiricik
AU  - Ozcan Yildiz
AU  - Ömer Fatih Olmez
PY  - 2026
JO  - The Oncologist
DO  - 10.1093/oncolo/oyag372
UR  - https://doi.org/10.1093/oncolo/oyag372
ER  -

APA

Aysan, M., Koylu, B., Bayramgil, A., Unal, D., Karaalioğlu, B., Bilici, A., Selçukbiricik, F., Yildiz, O., & Olmez, Ö. F. (2026). Comparative safety of concurrent adjuvant trastuzumab emtansine <i>versus</i> trastuzumab with radiotherapy in HER2-positive early breast cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyag372

Source records

crossref · retrieved 2026-09-25T17:12:21.417Z